All In Biotech

Drug Trial Radar · NCT07390383

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 04]

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

May 30, 2028

Study completion May 30, 2028

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
Collaborators
Peking University Cancer Hospital & Institute
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.

Conditions

  • Advanced Solid Tumour

Interventions

  • LBL-024 for InjectionDrug

    Intravenous infusion

  • Capecitabine tabletsDrug

    Oral administration

  • Tislelizumab InjectionDrug

    Intravenous infusion

  • Oxaliplatin injectionDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Not yet recruiting

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.